Bladder Cancer Weekly

February 22, 2026

Videos

Peer-to-Peer Clinical Conversations

A Multi-Center Study Examines Maintenance Schedules for Intermediate-Risk NMIBC - Roberto Contieri

Roberto Contieri

Roberto Contieri presents a retrospective multicenter study of 292 intermediate-risk Ta non-muscle-invasive bladder cancer patients from 13 Italian centers.

View

Design and Safety of a Patient-Centric Expanded Access Program with Cretostimogene Grenadenorepvec - Sarah Psutka

Sarah Psutka

Sarah Psutka discusses cretostimogene grenadenorepvec expanded access program with Ashish Kamat.

View

Beyond the Abstracts

Outcomes of Immune Checkpoint Inhibitor Rechallenge in Advanced Urothelial Carcinoma: Results from a Global Real-World Evidence Study - Beyond the Abstract

Trimodal Treatment vs Radical Cystectomy for Muscle-invasive Bladder Cancer: the Neglected Impact of Informative Censoring. A Systematic Review and Meta-analysis - Beyond the Abstract

Conference Coverage

SUO 2025: Baseline Urinary Tumor DNA, Minimal Residual Disease and Genomic Disease Burden in Relation to Clinical Response to INLEXZO™ in the Phase 2b SunRISe-1 Trial

SUO 2025: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel Combination (NDV-01) in High-Risk NMIBC: Update with 9-month Complete Response Data

ESMO 2025: TiP: INTerpath-011: A Phase 2 Study of Intismeran Autogene (V940/mRNA-4157) + BCG Versus BCG Alone for High-Risk NMIBC

ESMO 2025: Intravesical Recombinant BCG Followed by Perioperative Chemo-Immunotherapy (Chemo-IO) for Patients with Muscle-Invasive Bladder Cancer (MIBC): Interim Analysis of SAKK 06/19 Study

ASTRO 2025: Bladder Only vs. Whole Pelvis Radiotherapy in Trimodality Treatment for Lymph Node Negative Urothelial Muscle-Invasive Bladder Cancer: A Systematic Review and Meta-Analysis

Articles

Editor Selected Abstracts and Commentaries

Bladder Cancer

Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.

Monitoring of plasma and urine tumor-derived DNA to inform bladder-sparing approaches for patients with muscle-invasive bladder cancer.

Leisure-Time Physical Activity and Cancer Mortality Among Cancer Survivors.

Oncologic outcomes after robot assisted radical cystectomy in patients with clinically positive lymph nodes (cN1): a tertiary referral center experience.

Optimal adjuvant intravesical therapy for intermediate risk non-muscle invasive bladder cancer; oncological and patient-reported outcomes of randomized controlled trial.

ImmunityBio Receives Authorization from the European Commission for ANKTIVA® with BCG for Non-Muscle Invasive Bladder Cancer Carcinoma in Situ, Expanding Global Access to 33 Countries

From Lichtleiter to Laser: A 200-Year Odyssey of Transurethral Resection of Bladder Tumors.

Treatment Selection for Non-Muscle-Invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.

Survival Outcomes of BCG Only, BCG Plus EMDA-MMC or Upfront Radical Cystectomy in High-Risk Non-Muscle Invasive Bladder Cancers (NMIBCs): A Multicentre, International, Collaborative Study from Tertiary Referral Institutions.

Predictors of adherence to surveillance cystoscopy for patients with non-muscle invasive bladder cancer.

Effect of extending the oral administration period of 5-aminolevulinic acid on diagnostic accuracy and treatment outcomes for non-muscle-invasive bladder cancer.

Radiotherapy with twice weekly Gemcitabine and Cisplatin compared to Cisplatin alone for organ preservation in muscle-invasive bladder cancer: results of the GETUG V04 randomized phase II trial.

Optimizing oncological outcomes in high-grade non-muscle invasive bladder cancer: The impact of a surgeon-led treatment pathway.

Differences in Bladder Cancer Diagnosis by Demographic Factors: A Simulation Modeling Analysis.

Intraoperative evaluation of detrusor muscle during transurethral resection of bladder tumour using confocal fluorescent microscopy.

Efficacy of early intravesical instillation of hyaluronic acid after transurethral resection of non-muscle-invasive bladder cancers: An open-label, prospective, single-center, randomized, controlled and parallel-group pilot study.

A Multi-Modal Approach for Decision Making in Bladder Cancer - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Bladder Cancer Weekly

Bladder Cancer

Login